CDIO Profile
Cardio Diagnostics Holdings, Inc. is a biotechnology firm specializing in the development and commercialization of epigenetics-based clinical tests focused on cardiovascular disease. Headquartered in Chicago, Illinois, the company was established in 2017 with a mission to innovate within the field of cardiovascular diagnostics.
The flagship product offered by Cardio Diagnostics Holdings is Epi+Gen, a clinically advanced test designed for assessing the risk of symptomatic coronary heart disease (CHD) over a three-year period. This test specifically targets CHD events, including heart attacks, utilizing epigenetic markers to provide predictive insights into an individual's cardiovascular health.
By leveraging epigenetics, Cardio Diagnostics Holdings aims to enhance early detection and personalized management of cardiovascular risks, thereby potentially improving patient outcomes through proactive healthcare interventions.
As a relatively young company in the biotechnology sector, Cardio Diagnostics Holdings continues to focus on advancing its proprietary technologies and expanding its presence in the field of cardiovascular diagnostics.
|
